From Analysis:
Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron chelation therapies
Iron-dependent cell death (ferroptosis) as a mechanism in ALS and motor neuron diseases. Focus on GPX4 (glutathione peroxidase 4), lipid peroxidation, system Xc- cystine/glutamate antiporter, and iron chelation therapies.
Molecular Mechanism and Rationale
The Nuclear Factor Erythroid 2-Related Factor 2 (NRF2, encoded by NFE2L2) represents a master transcriptional regulator of cellular antioxidant defense systems, operating through a sophisticated molecular machinery that has emerged as a critical therapeutic target in amyotrophic lateral sclerosis (ALS). Under basal conditions, NRF2 is maintained at low cytoplasmic levels through its interaction with Kelch-like ECH-associated protein 1 (KEAP1), a substrate adaptor for the Cullin 3 (CUL3)-based E3 ubiquitin ligase complex. KEAP1 contains multiple cysteine residues, particularly Cys151, Cys273, and Cys288, which function as redox sensors that undergo oxidative modification in response to cellular stress signals.
...No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Oxidative Stress
ROS/Electrophiles"]
B["KEAP1 Cysteine Oxidation
Sensor Inactivation"]
C["NRF2 Release
KEAP1-NRF2 Dissociation"]
D["NRF2 Nuclear Translocation
ARE Binding"]
E["Phase II Enzyme Expression
HO1/NQO1/GCLC/GCLM"]
F["GSH Synthesis
Antioxidant Pool Replenished"]
G["ROS Detoxification
Cytoprotection"]
H["NRF2 Reduced in AD
Oxidative Vulnerability"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
H -.->|"impairs"| C
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Based on my comprehensive research gathering literature evidence and computational findings, I now present 6 novel therapeutic hypotheses for ferroptosis in ALS and motor neuron diseases.
Description: Small molecule mimetics of the GPX4 selenopeptide active site (Sec-γ-Glu-Cys-Gly) could directly restore phospholipid hydroperoxide reduction capacity in ALS motor neurons, circumventing the translational limitations observed with full-le
Before evaluating individual hypotheses, several overarching issues must be addressed:
1. Translational Disconnect: While the preclinical evidence for ferroptosis involvement in ALS is compelling, clinical translation has been disappointing. The neurodegenerative disease field has a well-documented history of promising preclinical findings that fail in human trials.
2. Causal vs. Correlative Evidence: Many findings demonstrate ferroptosis markers in ALS tissues, but establishi
Of the seven hypotheses presented, five survive critical evaluation with sufficient translational potential to warrant serious investigation, though each faces distinct pharmacological, clinical, or commercial challenges. The most promising candidates require biomarker-stratified patient selection and combination approaches rather than single-agent interventions. The field has been significantly de-risked by existing clinical trial infrastructure for iron chelation and NRF2 activat
{"ranked_hypotheses":[{"title":"GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade","description":"Small molecule mimetics of the GPX4 selenopeptide active site (Sec-γ-Glu-Cys-Gly) could directly restore phospholipid hydroperoxide reduction capacity in ALS motor neurons, circumventing translational limitations observed with full-length protein delivery.","target_gene":"GPX4","dimension_scores":{"mechanistic_plausibility":0.82,"evidence_strength":0.78,"novelty":0.65,"feasibility":0.52,"therapeutic_potential":0.72,"druggability":0.48,"safety_profile":0.55,"competitive_landscap
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for NRF2 (NFE2L2), KEAP1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No related hypotheses found
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
ferroptosis["ferroptosis"] -->|causes| motor_neuron_death["motor neuron death"]
Dimethyl_fumarate["Dimethyl fumarate"] -->|activates| NRF2["NRF2"]
GPX4["GPX4"] -.->|reduces| phospholipid_hydroperoxid["phospholipid hydroperoxides"]
SLC7A11["SLC7A11"] -->|modulates| glutamate_release["glutamate release"]
xCT_expression["xCT expression"] -->|enriched in| microglia["microglia"]
xCT_levels["xCT levels"] -->|increases during| ALS_disease_progression["ALS disease progression"]
GPX4_overexpression["GPX4 overexpression"] -->|protective against| SOD1G93A_mouse_ALS["SOD1G93A mouse ALS"]
GPX4_1["GPX4"] -->|associated with| ALS["ALS"]
SLC7A11_2["SLC7A11"] -->|causes| excitotoxicity["excitotoxicity"]
GPX4_depletion["GPX4 depletion"] -->|causes| ALS_3["ALS"]
SLC7A11_4["SLC7A11"] -->|enhances| glutamate_release_5["glutamate release"]
NRF2_activation["NRF2 activation"] -->|protective against| motor_neuron_death_6["motor neuron death"]
style ferroptosis fill:#4fc3f7,stroke:#333,color:#000
style motor_neuron_death fill:#4fc3f7,stroke:#333,color:#000
style Dimethyl_fumarate fill:#4fc3f7,stroke:#333,color:#000
style NRF2 fill:#4fc3f7,stroke:#333,color:#000
style GPX4 fill:#4fc3f7,stroke:#333,color:#000
style phospholipid_hydroperoxid fill:#4fc3f7,stroke:#333,color:#000
style SLC7A11 fill:#4fc3f7,stroke:#333,color:#000
style glutamate_release fill:#4fc3f7,stroke:#333,color:#000
style xCT_expression fill:#4fc3f7,stroke:#333,color:#000
style microglia fill:#4fc3f7,stroke:#333,color:#000
style xCT_levels fill:#4fc3f7,stroke:#333,color:#000
style ALS_disease_progression fill:#ef5350,stroke:#333,color:#000
style GPX4_overexpression fill:#4fc3f7,stroke:#333,color:#000
style SOD1G93A_mouse_ALS fill:#ef5350,stroke:#333,color:#000
style GPX4_1 fill:#4fc3f7,stroke:#333,color:#000
style ALS fill:#ef5350,stroke:#333,color:#000
style SLC7A11_2 fill:#4fc3f7,stroke:#333,color:#000
style excitotoxicity fill:#4fc3f7,stroke:#333,color:#000
style GPX4_depletion fill:#4fc3f7,stroke:#333,color:#000
style ALS_3 fill:#ef5350,stroke:#333,color:#000
style SLC7A11_4 fill:#4fc3f7,stroke:#333,color:#000
style glutamate_release_5 fill:#4fc3f7,stroke:#333,color:#000
style NRF2_activation fill:#4fc3f7,stroke:#333,color:#000
style motor_neuron_death_6 fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-16 | completed
No comments yet. Be the first to comment!